1.Efficacy Analysis of Suprapapillary versus Transpapillary Self-Expandable Metal Stents According to the Level of Obstruction in Malignant Extrahepatic Biliary Obstruction
Sung Yong HAN ; Tae Hoon LEE ; Sung Ill JANG ; Dong Uk KIM ; Jae Kook YANG ; Jae Hee CHO ; Min Je SUNG ; Chang-Il KWON ; Jin-Seok PARK ; Seok JEONG ; Don Haeng LEE ; Sang-Heum PARK ; Dong Ki LEE
Gut and Liver 2023;17(5):806-813
Background/Aims:
The use of a self-expandable metal stent (SEMS) is recommended for unresectable malignant biliary obstruction (MBO). Stent-related adverse events might differ according to the position of the stent through the ampulla of Vater (AOV). We retrospectively evaluated SEMS patency and adverse events according to the position of the SEMS.
Methods:
In total, 280 patients who underwent endoscopic SEMS placement due to malignant distal biliary obstruction were analyzed retrospectively. Suprapapillary and transpapillary SEMS insertions were performed on 51 patients and 229 patients, respectively.
Results:
Between the suprapapillary group (SPG) and transpapillary group (TPG), the stent patency period was not significantly different (median [95% confidence interval]: 107 days [82.3 to 131.7] vs 120 days [99.3 to 140.7], p=0.559). There was also no significant difference in the rate of adverse events. In subgroup analysis, the stent patency for an MBO located within 2 cm from the AOV was found to be significantly shorter than that for an MBO located more than 2 cm from the AOV in the SPG (64 days [0 to 160.4] vs 127 days [82.0 to 171.9], p<0.001) and TPG (87 days [52.5 to 121.5] vs 130 [97.0 to 162.9], p<0.001). Patients with an MBO located within 2 cm from the AOV in both groups had a higher percentage of duodenal invasion (SPG: 40.0% vs 4.9%, p=0.002; TPG: 28.6% vs 2.9%, p<0.001) than patients with an MBO located more than 2 cm from the AOV.
Conclusions
The SPG and TPG showed similar results in terms of stent patency and rate of adverse events. However, patients with an MBO located within 2 cm from the AOV had a higher percentage of duodenal invasion with shorter stent patency than those with an MBO located more than 2 cm from the AOV, regardless of stent position.
2.Risk of cervical dysplasia among human papillomavirus-infected women in Korea: a multicenter prospective study
Yoon PARK ; Tae Jin KIM ; Chang Sun HWANG ; Chi Heum CHO ; Dae Hoon JEONG ; Seok Ju SEONG ; Jae Kwan LEE ; Sooyoung HUR ; Mee Kyung KEE ; Jaehyun SEONG ; Moran KI
Journal of Gynecologic Oncology 2019;30(3):e50-
OBJECTIVE: Human papillomavirus (HPV) infection is the most important risk factor for cervical cancer, which progresses from precursor lesions with no symptom if left untreated. We compared the risk of cervical dysplasia among HPV-positive Korean women based on HPV types and infection patterns. METHODS: We observed participants of a 5-year multicenter prospective cohort study, comprising HPV-positive women with either atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion of the cervix at their enrollment. Follow-ups, comprising cytology and HPV DNA testing results, were included in the final analysis. Incidence was calculated for each infection pattern (persistent infection, incidental infection, and clearance). To investigate cervical dysplasia risk, we used Cox proportional hazard models adjusted for variables that were significantly different among infection patterns. From April 2010 to September 2017, 71 of 1,027 subjects developed cervical dysplasia more severe than high-grade squamous intraepithelial lesion of the cervix. RESULTS: Of these 71 subjects, persistent infection, incidental infection, and clearance were noted in 30, 39, and 2 individuals, respectively. Based on changes in DNA results during follow-up, cumulative incidence was 27.2%, 10.4%, and 0.5% for persistent infection, incidental infection, and clearance, respectively. Compared to clearance, the adjusted hazard ratios for cervical dysplasia were 51.6 and 24.1 for persistent and incidental infections, respectively (p < 0.001). CONCLUSION: Individuals persistently infected with the same HPV types during the follow-up period had the highest risk of severe cervical dysplasia. Hence, it is necessary to monitor HPV types and infection patterns to prevent severe cervical precancerous lesions.
Atypical Squamous Cells of the Cervix
;
Cervix Uteri
;
Cohort Studies
;
DNA
;
Female
;
Follow-Up Studies
;
Human Papillomavirus DNA Tests
;
Humans
;
Incidence
;
Korea
;
Papillomavirus Infections
;
Proportional Hazards Models
;
Prospective Studies
;
Republic of Korea
;
Risk Factors
;
Squamous Intraepithelial Lesions of the Cervix
;
Uterine Cervical Dysplasia
;
Uterine Cervical Neoplasms
3.Which strategy is better for resectable synchronous liver metastasis from colorectal cancer, simultaneous surgery, or staged surgery? Multicenter retrospective analysis
Bong Hyeon KYE ; Suk Hwan LEE ; Woon Kyung JEONG ; Chang Sik YU ; In Ja PARK ; Hyeong Rok KIM ; Jin KIM ; In Kyu LEE ; Ki Jea PARK ; Hong Jo CHOI ; Ho Young KIM ; Jeong Heum BAEK ; Yoon Suk LEE
Annals of Surgical Treatment and Research 2019;97(4):184-193
PURPOSE: The optimal treatment for synchronous liver metastasis (LM) from colorectal cancer (CRC) depends on various factors. The present study was intended to investigate the oncologic outcome according to the time of resection of metastatic lesions. METHODS: Data from patients who underwent treatment with curative intent for primary CRC and synchronous LM between 2004 and 2009 from 9 university hospitals in Korea were collected retrospectively. One hundred forty-three patients underwent simultaneous resection for primary CRC and synchronous LM (simultaneous surgery group), and 65 patients were treated by 2-stage operation (staged surgery group). RESULTS: The mean follow-up length was 41.2 ± 24.6 months. In the extent of resection for hepatic metastasis, major hepatectomy was more frequently performed in staged surgery group (33.8% vs. 8.4%, P < 0.001). The rate of severe complications of Clavien-Dindo classification grade III or more was not significantly different between the 2 groups. The 3-year overall survival (OS) rate was 85.0% in staged surgery group and 69.4% in simultaneous surgery group (P = 0.013), and the 3-year recurrence-free survival (RFS) rate was 46.4% in staged surgery group and 30.2% in simultaneous surgery group (P = 0.143). In subgroup analysis based on the location of primary CRC, the benefit of staged surgery for OS and RFS was clearly shown in rectal cancer (P = 0.021 and P = 0.015). CONCLUSION: Based on our results, staged surgery with or without neoadjuvant chemotherapy should be considered for resectable synchronous LM from CRC, especially in rectal cancer, as a safe and fairly promising option.
Classification
;
Colorectal Neoplasms
;
Drug Therapy
;
Follow-Up Studies
;
Hepatectomy
;
Hospitals, University
;
Humans
;
Korea
;
Liver
;
Neoplasm Metastasis
;
Rectal Neoplasms
;
Retrospective Studies
4.Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study.
Byung Mo KANG ; Jeong Heum BAEK ; Sun Jin PARK ; Seong Kyu BAEK ; Ki Jae PARK ; Hong Jo CHOI ; Byung Noe BAE ; Sun Keun CHOI ; Kap Tae KIM ; Jin Su KIM ; Suk Hwan LEE
Annals of Coloproctology 2018;34(3):144-151
PURPOSE: This study compared the oncologic impact of postoperative chemotherapy and chemoradiotherapy on patients with rectal cancer without preoperative chemoradiation. METHODS: This retrospective study analyzed 713 patients with a mean follow-up of 58 months who had undergone radical resection for stage II/III rectal cancer without preoperative treatment in nine hospitals from January 2004 to December 2009. The study population was categorized a chemotherapy group (CG, n = 460) and a chemoradiotherapy group (CRG, n = 253). Five-year overall survival (OS) and disease-free survival (DFS) were analyzed, and independent factors predicting survival were identified. RESULTS: The patients in the CRG were significantly younger (P < 0.001) and had greater incidences of low rectal cancer (P < 0.001) and stage III disease (P < 0.001). Five-year OS (P = 0.024) and DFS (P = 0.012) were significantly higher in the CG for stage II disease; however, they were not significantly different for stage III disease. In the multivariate analysis, independent predictive factors were male sex, low rectal cancer and stage III disease for OS and male sex, abdominoperineal resection, stage III disease and tumor-positive circumferential margin for DFS. However, adjuvant therapy type did not independently affect OS (hazard ratio [HR], 1.243; 95% confidence interval [CI], 0.794–1.945; P = 0.341) and DFS (HR, 1.091; 95% CI, 0.810–1.470; P = 0.566). CONCLUSION: Adjuvant therapy type did not affect survival of stage II/III rectal cancer patients without neoadjuvant chemoradiotherapy. These results suggest that adjuvant therapy can be chosen based on the patient’s condition and the policies of the surgeons and hospital facilities.
Chemoradiotherapy
;
Disease-Free Survival
;
Drug Therapy
;
Follow-Up Studies
;
Humans
;
Incidence
;
Male
;
Multivariate Analysis
;
Rectal Neoplasms*
;
Retrospective Studies*
;
Surgeons
5.Risk factors for cytological progression in HPV 16 infected women with ASC-US or LSIL: The Korean HPV cohort.
Kyeong A SO ; Seon Ah KIM ; Yoo Kyung LEE ; In Ho LEE ; Ki Heon LEE ; Jee Eun RHEE ; Mee Kyung KEE ; Chi Heum CHO ; Sung Ran HONG ; Chang Sun HWANG ; Mi Seon JEONG ; Ki Tae KIM ; Moran KI ; Soo Young HUR ; Jong Sup PARK ; Tae Jin KIM
Obstetrics & Gynecology Science 2018;61(6):662-668
OBJECTIVE: This study was to identify the risk factors for cytological progression in women with atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL). METHODS: We analyzed data from women infected with the human papillomavirus (HPV) who participated in the Korean HPV cohort study. The cohort recruited women aged 20–60 years with abnormal cervical cytology (ASC-US or LSIL) from April 2010. All women were followed-up at every 6-month intervals with cervical cytology and HPV DNA testing. RESULTS: Of the 1,158 women included, 654 (56.5%) and 504 (43.5%) women showed ASC-US and LSIL, respectively. At the time of enrollment, 143 women tested positive for HPV 16 (85 single and 58 multiple infections). Cervical cytology performed in the HPV 16-positive women showed progression in 27%, no change in 23%, and regression in 50% of the women at the six-month follow-up. The progression rate associated with HPV 16 infection was higher than that with infection caused by other HPV types (relative risk [RR], 1.75; 95% confidence interval [CI], 1.08–2.84; P=0.028). The cytological progression rate in women with persistent HPV 16 infection was higher than that in women with incidental or cleared infections (P < 0.001). Logistic regression analysis showed a significant relationship between cigarette smoking and cytological progression (RR, 4.15; 95% CI, 1.01–17.00). CONCLUSION: The cytological progression rate in HPV 16-positive women with ASC-US or LSIL is higher than that in women infected with other HPV types. Additionally, cigarette smoking may play a role in cytological progression.
Atypical Squamous Cells of the Cervix*
;
Cohort Studies*
;
Epidemiology
;
Female
;
Follow-Up Studies
;
Human papillomavirus 16*
;
Human Papillomavirus DNA Tests
;
Humans
;
Logistic Models
;
Papillomaviridae
;
Risk Factors*
;
Smoking
;
Squamous Intraepithelial Lesions of the Cervix
6.The Impact of High-Risk HPV Genotypes Other Than HPV 16/18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study.
Kyeong A SO ; Mi Jung KIM ; Ki Heon LEE ; In Ho LEE ; Mi Kyung KIM ; Yoo Kyung LEE ; Chang Sun HWANG ; Mi Seon JEONG ; Mee Kyung KEE ; Chun KANG ; Chi Heum CHO ; Seok Mo KIM ; Sung Ran HONG ; Ki Tae KIM ; Won Chul LEE ; Jong Sup PARK ; Tae Jin KIM
Cancer Research and Treatment 2016;48(4):1313-1320
PURPOSE: The purpose of this study is to evaluate the impact of high-risk human papillomaviruses (HPVs) other than HPV 16/18 on the natural course of atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL). MATERIALS AND METHODS: The study population was derived from the Korean HPV cohort (2010-2014). Women aged 20 to 60 who satisfied the criteria of having both HPV infection and abnormal cervical cytology of either ASC-US or LSIL were recruited from five institutions nationwide. Enrolled patients underwent cervical cytology and HPV DNA testing every 6 months. RESULTS: A total of 1,158 patients were enrolled. The 10 most common HPV types were HPV 16 (12.3%), 58 (10.0%), 56 (8.8%), 53 (8.4%), 52 (7.7%), 39 (6.2%), 18 (6.0%), 51 (5.7%), 68 (5.1%), and 66 (4.6%). Among these patients, 636 women were positive for high-risk HPVs other than HPV 16 or 18, and 429 women were followed for more than 6 months. Cytology evaluations showed progression in 15.3% of women, no change in 22.6%, and regression in 62.1% of women at 12 months. In cases of HPV 58 single infection, a more highly significant progression rate, compared to other high-risk types, was observed at 6 months (relative risk [RR], 3.3; 95% confidence interval [CI], 2.04 to 5.30; p < 0.001) and 12 months (RR, 5.03; 95% CI, 2.56 to 9.91; p < 0.001). CONCLUSION: HPV genotypes numbered in the 50s were frequent in Korean women with ASC-US and LSIL. HPV 58 was the second most common type, with a high progression rate of cervical cytology.
Atypical Squamous Cells of the Cervix
;
Cohort Studies*
;
Female
;
Genotype*
;
Human papillomavirus 16
;
Human Papillomavirus DNA Tests
;
Humans
;
Squamous Intraepithelial Lesions of the Cervix
7.The Korean guideline for cervical cancer screening.
Kyung Jin MIN ; Yoon Jae LEE ; Mina SUH ; Chong Woo YOO ; Myong Cheol LIM ; Jaekyung CHOI ; Moran KI ; Yong Man KIM ; Jae Weon KIM ; Jea Hoon KIM ; Eal Whan PARK ; Hoo Yeon LEE ; Sung Chul LIM ; Chi Heum CHO ; Sung Ran HONG ; Ji Yeon DANG ; Soo Young KIM ; Yeol KIM ; Won Chul LEE ; Jae Kwan LEE
Journal of the Korean Medical Association 2015;58(5):398-407
The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papilloma virus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The combination test (cytology with HPV test) is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within ten years (recommendation D).
Developed Countries
;
Female
;
Humans
;
Incidence
;
Korea
;
Mass Screening*
;
Papanicolaou Test
;
Papilloma
;
Uterine Cervical Neoplasms*
8.The Korean guideline for cervical cancer screening.
Kyung Jin MIN ; Yoon Jae LEE ; Mina SUH ; Chong Woo YOO ; Myong Cheol LIM ; Jaekyung CHOI ; Moran KI ; Yong Man KIM ; Jae Weon KIM ; Jea Hoon KIM ; Eal Whan PARK ; Hoo Yeon LEE ; Sung Chul LIM ; Chi Heum CHO ; Sung Ran HONG ; Ji Yeon DANG ; Soo Young KIM ; Yeol KIM ; Won Chul LEE ; Jae Kwan LEE
Journal of Gynecologic Oncology 2015;26(3):232-239
The incidence rate of cervical cancer in Korea is still higher than in other developed countries, notwithstanding the national mass-screening program. Furthermore, a new method has been introduced in cervical cancer screening. Therefore, the committee for cervical cancer screening in Korea updated the recommendation statement established in 2002. The new version of the guideline was developed by the committee using evidence-based methods. The committee reviewed the evidence for the benefits and harms of the Papanicolaou test, liquid-based cytology, and human papillomavirus (HPV) testing, and reached conclusions after deliberation. The committee recommends screening for cervical cancer with cytology (Papanicolaou test or liquid-based cytology) every three years in women older than 20 years of age (recommendation A). The cervical cytology combined with HPV test is optionally recommended after taking into consideration individual risk or preference (recommendation C). The current evidence for primary HPV screening is insufficient to assess the benefits and harms of cervical cancer screening (recommendation I). Cervical cancer screening can be terminated at the age of 74 years if more than three consecutive negative cytology reports have been confirmed within 10 years (recommendation D).
Adult
;
Age Factors
;
Aged
;
Early Detection of Cancer/adverse effects/*methods/standards
;
Evidence-Based Medicine
;
False Positive Reactions
;
Female
;
Humans
;
Hysterectomy
;
Middle Aged
;
Papillomavirus Infections/diagnosis
;
Papillomavirus Vaccines
;
Patient Selection
;
Pregnancy
;
Pregnancy Complications, Neoplastic/diagnosis
;
Republic of Korea
;
Review Literature as Topic
;
Uterine Cervical Neoplasms/*diagnosis
;
Vaginal Smears/adverse effects/methods/standards
;
Young Adult
9.Clinical Factors Related to Frailty Estimated by the Korean Frailty Index.
Hwee Soo JEONG ; Dong Wook LEE ; Ki Heum PARK ; Yong Kook LEE ; Sang Ho BAE ; Mi Jin KANG ; Min Sung SHIM ; Chen Hsuen TEONG
Journal of the Korean Geriatrics Society 2013;17(2):71-78
BACKGROUND: On the point of entering into the aged society, frailty will be recognized as a new geriatric problem in Korea. This study was conducted to identify clinical factors related to frailty in the community dwelling elderly. METHODS: This was a cross-sectional study comprised of 515 participants among 834 potential subjects who were residents of three towns in Gyeong-ju and had health check-ups at a university hospital in the same region. Using the Korean Frailty Index, those with a total score of 5 or more were considered frail and those with scores 3 to 4 as prefrail. Socio-demographics, anthropometry and laboratory data were the selected clinical factors. Those younger than 65 years or with incomplete data were excluded. Finally, 447 participants were analyzed. RESULTS: Among the participants, those identified as frail were 20 (4.5%), prefrail 72 (16.1%) and robust 355 (79.4%). By gender, the percentage of frail, prefrail and robust individuals were 3.2%, 17.4% and 79.5%, respectively, in men and 5.4, 15.2% and 79.4% in women (p=0.447). On ordinal logistic regression analysis, factors related to frailty were increased age (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.01 to 1.17), functional disability (OR, 8.88; 95% CI, 4.46 to 17.68), chronic disease such as pulmonary disease (OR, 4.69; 95% CI, 1.47 to 14.99) or hypertension (OR, 2.23; 95% CI, 1.15 to 4.32), increased waist circumference (OR, 1.06; 95% CI, 1.01 to 1.11), decreased serum cholesterol (OR, 0.98; 95% CI, 0.97 to 0.99) and elevated blood urea nitrogen (OR, 1.07; 95% CI, 1.01 to 1.14). CONCLUSION: Clinical factors related to frailty were age, functional disability, chronic disease, waist circumference, serum cholesterol and blood urea nitrogen. Primary physicians should assess frailty when seeing elderly patients who have these factors.
Aged
;
Anthropometry
;
Blood Urea Nitrogen
;
Cholesterol
;
Chronic Disease
;
Cross-Sectional Studies
;
Female
;
Humans
;
Hypertension
;
Korea
;
Logistic Models
;
Lung Diseases
;
Male
;
Waist Circumference
10.Establishment of a Korea HPV cohort study.
Won Chul LEE ; Sae Young LEE ; Yu Jin KOO ; Tae Jin KIM ; Soo Young HUR ; Sung Ran HONG ; Sung Soon KIM ; Mee Kyung KEE ; Jee Eun RHEE ; Joo Shil LEE ; Ho Sun CHOI ; Chi Heum CHO ; Ki Tae KIM ; Jong Sup PARK
Journal of Gynecologic Oncology 2013;24(1):59-65
We have designed a five-year multicentre prospective cohort study in women who are both human papillomavirus (HPV)-positive with either atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) of cervix. This study aimed to analyze the risk of developing a high-grade squamous intraepithelial lesion (HSIL) from either ASCUS or LSIL in HPV-positive women, so called 'progression' rate, to investigate differences in the progression rates according to HPV type-specific infection, and to evaluate the various factors associated with the persistence or clearance of HPV infection in the Korean population. At present, the study protocol composed of cervical cytology, HPV DNA testing, and questionnaire have been conducted actively since the first participant was enrolled in 2010. This study is the first nationwide Korea HPV cohort study. Our data will provide valuable information about not only the ambiguous cytology results of ASCUS and LSIL but also the effect of the specific HPV type and other various factors on the progression to HSIL. Finally, the results of our study will be helpful and applicable to determine the primary cervical cancer prevention strategies.
Cervical Intraepithelial Neoplasia
;
Cervix Uteri
;
Cohort Studies
;
Female
;
Human Papillomavirus DNA Tests
;
Humans
;
Korea
;
Uterine Cervical Neoplasms
;
Surveys and Questionnaires

Result Analysis
Print
Save
E-mail